Moreover, the 36-month beta value for FGEN is 0.67. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 5 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for FGEN is 93.37M and currently, short sellers hold a 5.48% of that float. On September 19, 2024, FGEN’s average trading volume was 2.24M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
FGEN) stock’s latest price update
The stock price of FibroGen Inc (NASDAQ: FGEN) has dropped by -6.27 compared to previous close of 0.45. Despite this, the company has seen a gain of 5.95% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-09 that FibroGen, Inc. (NASDAQ:FGEN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia – CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig – Chief Executive Officer Deyaa Adib – Chief Medical Officer Juan Graham – Chief Financial Officer Chris Chung – Senior Vice President, China Operations Conference Call Participants Dalton Greenwood – William Blair Dina Ramadane – Bank of America Paul Choi – Goldman Sachs Operator Good day and welcome to the FibroGen Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
FGEN’s Market Performance
FibroGen Inc (FGEN) has experienced a 5.95% rise in stock performance for the past week, with a 11.20% rise in the past month, and a -59.22% drop in the past quarter. The volatility ratio for the week is 9.56%, and the volatility levels for the past 30 days are at 10.59% for FGEN. The simple moving average for the past 20 days is 4.77% for FGEN’s stock, with a -63.83% simple moving average for the past 200 days.
Analysts’ Opinion of FGEN
Many brokerage firms have already submitted their reports for FGEN stocks, with BofA Securities repeating the rating for FGEN by listing it as a “Underperform.” The predicted price for FGEN in the upcoming period, according to BofA Securities is $2 based on the research report published on August 08, 2023 of the previous year 2023.
FGEN Trading at -32.96% from the 50-Day Moving Average
After a stumble in the market that brought FGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -85.67% of loss for the given period.
Volatility was left at 10.59%, however, over the last 30 days, the volatility rate increased by 9.56%, as shares surge +1.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.95% lower at present.
During the last 5 trading sessions, FGEN rose by +5.95%, which changed the moving average for the period of 200-days by -23.97% in comparison to the 20-day moving average, which settled at $0.4011. In addition, FibroGen Inc saw -52.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FGEN starting from Adib Deyaa, who purchase 22,123 shares at the price of $1.17 back on Jun 12 ’24. After this action, Adib Deyaa now owns 82,123 shares of FibroGen Inc, valued at $25,884 using the latest closing price.
Wettig Thane, the CEO of FibroGen Inc, purchase 50,000 shares at $1.91 during a trade that took place back on Mar 07 ’24, which means that Wettig Thane is holding 470,178 shares at $95,470 based on the most recent closing price.
Stock Fundamentals for FGEN
Current profitability levels for the company are sitting at:
- -0.92 for the present operating margin
- 0.77 for the gross margin
The net margin for FibroGen Inc stands at -0.97. The total capital return value is set at -1.1. Equity return is now at value -42790.17, with -41.65 for asset returns.
Based on FibroGen Inc (FGEN), the company’s capital structure generated -0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -1.92. The debt to equity ratio resting at -0.45. The interest coverage ratio of the stock is -7.55.
Currently, EBITDA for the company is -259.28 million with net debt to EBITDA at -0.17. When we switch over and look at the enterprise to sales, we see a ratio of 0.38. The receivables turnover for the company is 4.98for trailing twelve months and the total asset turnover is 0.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.41.
Conclusion
To wrap up, the performance of FibroGen Inc (FGEN) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
